ATE417102T1 - Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin - Google Patents

Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin

Info

Publication number
ATE417102T1
ATE417102T1 AT04718384T AT04718384T ATE417102T1 AT E417102 T1 ATE417102 T1 AT E417102T1 AT 04718384 T AT04718384 T AT 04718384T AT 04718384 T AT04718384 T AT 04718384T AT E417102 T1 ATE417102 T1 AT E417102T1
Authority
AT
Austria
Prior art keywords
odn
medicine
antisense oligonucleotides
against smad7
smad7
Prior art date
Application number
AT04718384T
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Giuliani Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani Int Ltd filed Critical Giuliani Int Ltd
Application granted granted Critical
Publication of ATE417102T1 publication Critical patent/ATE417102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
AT04718384T 2003-04-02 2004-03-08 Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin ATE417102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2003RM000149 ITRM20030149A1 (it) 2003-04-02 2003-04-02 Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico

Publications (1)

Publication Number Publication Date
ATE417102T1 true ATE417102T1 (de) 2008-12-15

Family

ID=29765741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718384T ATE417102T1 (de) 2003-04-02 2004-03-08 Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin

Country Status (21)

Country Link
US (18) US7700757B2 (de)
EP (1) EP1608753B1 (de)
JP (2) JP4559411B2 (de)
KR (1) KR100822972B1 (de)
CN (1) CN100556461C (de)
AT (1) ATE417102T1 (de)
AU (1) AU2004225666B2 (de)
CA (1) CA2520541C (de)
CY (1) CY1108870T1 (de)
DE (1) DE602004018288D1 (de)
DK (1) DK1608753T3 (de)
ES (1) ES2316970T3 (de)
IT (1) ITRM20030149A1 (de)
MX (1) MXPA05010549A (de)
NO (1) NO334022B1 (de)
NZ (1) NZ542718A (de)
PL (1) PL1608753T3 (de)
PT (1) PT1608753E (de)
RU (1) RU2339697C2 (de)
SI (1) SI1608753T1 (de)
WO (1) WO2004087920A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363182A1 (en) * 2001-11-02 2003-05-12 Ribopharma Ag Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RS56049B1 (sr) * 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
WO2010064146A2 (en) 2008-12-02 2010-06-10 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
IN2012DN00720A (de) 2009-07-06 2015-06-19 Ontorii Inc
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
RU2597972C2 (ru) * 2010-10-22 2016-09-20 Курна Инк. Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
RU2014105311A (ru) 2011-07-19 2015-08-27 Уэйв Лайф Сайенсес Пте. Лтд. Способы синтеза функционализованных нуклеиновых кислот
AU2012307336B2 (en) 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy
IN2014DN08158A (de) * 2012-04-18 2015-05-01 Nogra Pharma Ltd
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
PT2872485T (pt) 2012-07-13 2021-03-05 Wave Life Sciences Ltd Grupo auxiliar assimétrico
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
NZ711564A (en) * 2013-03-15 2020-04-24 Nogra Pharma Ltd Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP3008184A1 (de) * 2013-06-13 2016-04-20 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und pharmazeutische zusammensetzungen zur behandlung von erythropoetischer protoporphyrie
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
CN106068325B (zh) 2014-01-16 2021-07-09 波涛生命科学有限公司 手性设计
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3207136A1 (de) 2014-10-17 2017-08-23 Nogra Pharma Limited Verfahren und zusammensetzungen zur behandlung eines patienten mit einem smad7-antisense-oligonukleotid
EP3213070A2 (de) * 2014-10-17 2017-09-06 Nogra Pharma Limited Verfahren zur dosierung und überwachung einer smad7-antisense-oligonukleotidbehandlung unter verwendung von mit biomarkerlevels
JP2017532982A (ja) * 2014-10-17 2017-11-09 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７アンチセンスオリゴヌクレオチドの同位体置換体
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US9688993B2 (en) 2015-02-13 2017-06-27 Idera Pharmaceuticals, Inc. Toll-like receptor 9 antagonist and methods of use thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
WO2017059225A1 (en) * 2015-09-30 2017-04-06 Celgene Corporation Tlr modulators and methods of use
JP2019505598A (ja) * 2016-02-23 2019-02-28 セルジーン アルパイン インベストメント カンパニー Ｉｉ， エルエルシー Ｓｍａｄ７の阻害を用いて、腸線維症を治療する方法
US11134889B2 (en) * 2016-12-14 2021-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. MODULATORS OF SMAD7 EXPRESSION
WO2019133949A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Therapeutics of ptd-smad7 fusion proteins
US10768615B2 (en) * 2018-02-26 2020-09-08 Sanskar Agrawal System and method for automated hospital beds

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096722A (en) * 1990-08-14 2000-08-01 Isis Pharmaceuticals Inc. Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
RU95104940A (ru) * 1992-07-27 1997-01-10 Хайбрайдон Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
US6884787B2 (en) * 2001-07-14 2005-04-26 Isis Pharmaceuticals, Inc. Antisense modulation of transforming growth factor-beta 3 expression
EP0667148B1 (de) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
US20020177568A1 (en) * 1992-12-07 2002-11-28 Stinchcomb Dan T. Enzymatic nucleic acid treatment of diseases or conditions related to levels of NF-kappa B
JP3555952B2 (ja) * 1993-04-30 2004-08-18 バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
CA2247246A1 (en) 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US6099823A (en) 1996-02-16 2000-08-08 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JPH10295381A (ja) * 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
EP0983360A1 (de) * 1997-05-20 2000-03-08 Ludwig Institute For Cancer Research Smad7 und dessen anwendungen
CA2294988C (en) * 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
HUP0101731A2 (hu) 1998-03-27 2001-09-28 Eli Lilly And Co. Eljárás érrendszeri betegségek kezelésére és megelőzésére
JPH11335269A (ja) * 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
WO1999060012A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US5962673A (en) 1998-11-20 1999-10-05 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-alpha expression
US6479465B2 (en) * 1999-03-24 2002-11-12 The United States Of America As Represented By The Department Of Health And Human Services Methods of treating colitis using STAT-4 anti-sense oligonucleotides
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
CA2392398A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20020147140A1 (en) * 2000-01-31 2002-10-10 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6613751B2 (en) 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1268774A2 (de) * 2000-03-21 2003-01-02 Elitra Pharmaceuticals, Inc. Identifizierung von essentiellen genen in prokaryote
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
EP1294947A2 (de) 2000-06-30 2003-03-26 Epigenomics AG Verfahren und nukleinsäuren für die pharmakogenomische methyllationsanalyse
US20030134324A1 (en) 2000-08-07 2003-07-17 Munger William E. Identifying drugs for and diagnosis of Benign Prostatic Hyperplasia using gene expression profiles
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
US20030087259A1 (en) 2001-04-18 2003-05-08 Clancy Brian M. Methods and compositions for regulating bone and cartilage formation
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
AU2002363182A1 (en) * 2001-11-02 2003-05-12 Ribopharma Ag Smad7 inhibitors for the treatment of cns diseases
EP1308459A3 (de) 2001-11-05 2003-07-09 Research Association for Biotechnology Vollständige cDNA-Sequenzen
JP2003135075A (ja) * 2001-11-05 2003-05-13 Research Association For Biotechnology 新規な全長ｃＤＮＡ
US20060263774A1 (en) 2002-11-01 2006-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004053099A2 (en) * 2002-12-10 2004-06-24 The Scripps Research Institute A method for treatment of drug addiction and for screening of pharmaceutical agents therefor
WO2004083389A2 (en) 2003-03-13 2004-09-30 Exelixis Inc. Mbcats as modifiers of the beta-catenin pathway and methods of use
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20040265833A1 (en) * 2003-06-23 2004-12-30 Cathy Lofton-Day Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
US20070105114A1 (en) 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
ITRM20030393A1 (it) 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
FR2862659B1 (fr) 2003-11-21 2006-02-10 Pasteur Institut Genome de legionella pneumophila souche paris- applications diagnostiques et epidemiologiques
WO2005077403A1 (en) 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
CA2558667A1 (en) 2004-02-27 2005-09-15 Antisense Pharma Gmbh Antisense oligonucleotides for inhibiting the formation of metastases in cancer
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
WO2007022642A2 (en) 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US20080032943A1 (en) 2005-11-04 2008-02-07 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
WO2007099345A1 (en) 2006-03-02 2007-09-07 Betagenon Ab Medical use of bmp-2 and/ or bmp-4
EP2012815A4 (de) 2006-04-14 2009-12-09 Massachusetts Inst Technology Identifikation und modulierung molekularer pfade zur vermittlung neuronaler plastizität
US20100099083A1 (en) 2006-07-26 2010-04-22 Genizon Biosciences Inc Crohn disease susceptibility gene
WO2008046964A2 (en) 2006-10-16 2008-04-24 Panu Jaakkola Novel useful inhibitors
WO2009151600A2 (en) 2008-06-10 2009-12-17 Tufts University Smad proteins control drosha-mediated mirna maturation
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
US8110355B2 (en) 2009-02-20 2012-02-07 GenRemedy, LLC Methods for identifying agents that inhibit cell migration, promote cell adhesion and prevent metastasis
AU2012307336B2 (en) 2011-09-15 2017-08-24 Nogra Pharma Limited Methods for monitoring responsiveness to anti-SMAD7 therapy
IN2014DN08158A (de) 2012-04-18 2015-05-01 Nogra Pharma Ltd
NZ711564A (en) 2013-03-15 2020-04-24 Nogra Pharma Ltd Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
EP3213070A2 (de) 2014-10-17 2017-09-06 Nogra Pharma Limited Verfahren zur dosierung und überwachung einer smad7-antisense-oligonukleotidbehandlung unter verwendung von mit biomarkerlevels
EP3207136A1 (de) 2014-10-17 2017-08-23 Nogra Pharma Limited Verfahren und zusammensetzungen zur behandlung eines patienten mit einem smad7-antisense-oligonukleotid
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017144689A1 (en) 2016-02-24 2017-08-31 Nogra Pharma Limited Methods of treating celiac disease using smad7 inhibition
EP3562943A1 (de) 2016-12-30 2019-11-06 Nogra Pharma Limited Zusammensetzungen aus smad7-antisense-oligonukleotid und verfahren zur behandlung oder prävention von psoriasis

Also Published As

Publication number Publication date
ITRM20030149A0 (it) 2003-04-02
US8106182B2 (en) 2012-01-31
US20090156539A1 (en) 2009-06-18
RU2005133711A (ru) 2006-05-10
US9518264B2 (en) 2016-12-13
US20150211011A1 (en) 2015-07-30
US8907078B2 (en) 2014-12-09
CA2520541C (en) 2012-05-08
US20140142163A1 (en) 2014-05-22
US9951334B2 (en) 2018-04-24
US20070167385A1 (en) 2007-07-19
SI1608753T1 (sl) 2009-04-30
JP2006521815A (ja) 2006-09-28
CN100556461C (zh) 2009-11-04
NO20054861L (no) 2005-10-20
CN1788086A (zh) 2006-06-14
NZ542718A (en) 2007-04-27
US8648186B2 (en) 2014-02-11
DE602004018288D1 (de) 2009-01-22
US9096854B1 (en) 2015-08-04
US9006418B2 (en) 2015-04-14
RU2339697C2 (ru) 2008-11-27
KR100822972B1 (ko) 2008-04-17
US20100317719A1 (en) 2010-12-16
CY1108870T1 (el) 2014-07-02
US20070042985A1 (en) 2007-02-22
US20180030450A1 (en) 2018-02-01
ITRM20030149A1 (it) 2004-10-03
NO334022B1 (no) 2013-11-18
PT1608753E (pt) 2009-02-16
US10738309B2 (en) 2020-08-11
WO2004087920A1 (en) 2004-10-14
US10036022B2 (en) 2018-07-31
JP4559411B2 (ja) 2010-10-06
US20140256788A1 (en) 2014-09-11
US9382541B2 (en) 2016-07-05
JP2010193906A (ja) 2010-09-09
PL1608753T3 (pl) 2009-06-30
US20200325480A1 (en) 2020-10-15
MXPA05010549A (es) 2006-05-25
CA2520541A1 (en) 2004-10-14
US9279126B2 (en) 2016-03-08
EP1608753A1 (de) 2005-12-28
US20200181622A1 (en) 2020-06-11
KR20050118705A (ko) 2005-12-19
US20160304876A1 (en) 2016-10-20
US20150337312A1 (en) 2015-11-26
US20170253880A1 (en) 2017-09-07
AU2004225666B2 (en) 2008-07-10
US10633660B2 (en) 2020-04-28
US7807818B2 (en) 2010-10-05
US20150218561A1 (en) 2015-08-06
US20120136043A1 (en) 2012-05-31
EP1608753B1 (de) 2008-12-10
DK1608753T3 (da) 2009-04-14
AU2004225666A2 (en) 2004-10-14
US20130203839A1 (en) 2013-08-08
US20190211336A1 (en) 2019-07-11
AU2004225666A1 (en) 2004-10-14
JP5039172B2 (ja) 2012-10-03
ES2316970T3 (es) 2009-04-16
US20160177306A1 (en) 2016-06-23
US7700757B2 (en) 2010-04-20
US9605264B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
ATE417102T1 (de) Antisense-oligonukleotide (odn) gegen smad7 und ihre verwendung in der medizin
NO20092639L (no) 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
ATE518011T1 (de) Erhöhte expression von t- zellenrezeptorvermittelter tumornekrosefaktorsuperfamilie und chemokin-mrna in peripheren blut leukozyten bei patienten mit morbus& xa;crohn
ATE489956T1 (de) Formulierungen enthaltend salicylate und deren verwendung zur behandlung von entzündlicher darmerkrankung
CL2004000526A1 (es) Compuestos derivados de dibenzofurano, carbazoles, inhibidores de fosfodiesterasa tipo 4; procedimiento de preparacion; y su uso en el tratamiento de trastornos y condiciones inflamatorias, del sistema nervioso central y diabetes insulino resistente.
DE60144514D1 (de) Verwendung von il-18 inhibitoren
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
AU2378402A (en) Imaging, diagnosis and treatment of disease
NO20052956D0 (no) Defensinprotiner
ATE465743T1 (de) Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
SE0302304D0 (sv) Novel compounds
NO20053903L (no) Nukleotidlipidesterderivater.
GB0418388D0 (en) Cell therapy
WO2009141731A3 (en) The large form of human 2', 5'-oligoadenylate synthetase oas3 for preventing or treating infection with positive-sense single-stranded rna viruses
IL169256A0 (en) Metalloprotease proteins
EA202192330A1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения
ATE544856T1 (de) Peptid- und nukleotidsequenzen von anisakis spp. und ihre verwendung
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
MD2872G2 (ro) Metodă de pronostic al riscului apariţiei hiperplaziei dishormonale a glandei mamare
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
DE60330565D1 (de) Anti-fragilis Antikörper und dessen Verwendungen
ATE402147T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
WO2007049062A3 (en) Vwfa-domain containing proteins
WO2006051333A3 (en) Leucine-rich repeat (lrr) motif containing proteins

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608753

Country of ref document: EP